Note: This document contains side effect information about vincristine liposome. Some of the dosage forms listed on this page may not apply to the brand name Marqibo.
Common side effects of Marqibo include: anemia, constipation, neutropenia, and thrombocytopenia. Other side effects include: asthenia, increased serum aspartate aminotransferase, and intestinal obstruction. See below for a comprehensive list of adverse effects.
Applies to vincristine liposome: intravenous suspension
Intravenous route (Suspension)
For intravenous use only. Fatalities have occurred when given by other routes, including intrathecal administration. VinCRIStine sulfate liposome injection has different dosage recommendations than vinCRIStine sulfate injection. Verify drug name and dose before preparation and administration to avoid overdosage.
Along with its needed effects, vincristine liposome (the active ingredient contained in Marqibo) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking vincristine liposome:
Incidence not known
Some side effects of vincristine liposome may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
Applies to vincristine liposome: intravenous kit
Common (1% to 10%): Hypotension, cardiac arrest, vascular disorder
Very common (10% or more): Nausea (52%), diarrhea (37%), decreased appetite (33%)
Common (1% to 10%): Constipation, abdominal pain, ileus/colonic pseudo-obstruction
Side effects that have resulted in non-leukemia related deaths: Brain infarct, intracerebral hemorrhage, liver failure, multisystem organ failure, pneumonia and septic shock, respiratory failure, pulmonary hemorrhage, sudden cardiac death
Very common (10% or more): Febrile neutropenia (38%), neutropenia (31.3%), anemia (34%), thrombocytopenia (16.9%)
Frequency not reported: Neutropenia, thrombocytopenia
Frequency not reported: Increased aspartate aminotransferase, tumor lysis syndrome
Frequency not reported: Asthenia, muscular weakness, musculoskeletal pain
Very common (10% or more): Peripheral neuropathy (39%), insomnia (32%)
Common (1% to 10%): Peripheral sensory and motor neuropathy, decreased vibratory sense, facial palsy, hyporeflexia, asthenia
Very common (10% or more): Pyrexia (15%), fatigue (12%)
Frequency not reported: Mental status changes
Common (1% to 10%): Respiratory distress, respiratory failure, pneumonia
Common (1% to 10%): Septic shock, staphylococcal bacteremia
Frequency not reported: Extravasation tissue injury
Frequency not reported: Hepatic toxicity
Very common (10% or more): Pyrexia (43%), fatigue (41%)
Frequency not reported: Pain, septic shock, staphylococcal bacteremia
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Marqibo